SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Oscient Pharmaceuticals Corp. (OSCI)
An SI Board Since May 1996
Posts SubjectMarks Bans Symbol
1154 42 0 GENE
Emcee:  Tara Cobble Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
1004<b>Oscient Pharmaceuticals Completes Enrollment in Phase II Trial of RamopIan@SI-6/21/2004
1003Yes, during the past month there's seems to be a strong pick up in institutiIan@SI-6/3/2004
1002Hi Ian, Nice GRUB! This news can't hurt things any. The price seems to haveOldAIMGuy-6/3/2004
1001Some info on Factive: patientcarenp.com Gemifloxacin Class Fluoroquinolone caly-6/2/2004
100008:10 ET GENE initiated with Strong Buy and $9 tgt at First Albany; 3 others 4.Ian@SI-6/2/2004
999Oscient Pharma GENE inititiated at First Albany with Strong Buy and a target of Ian@SI-6/2/2004
998Oscient Pharmaceuticals added to NASDAQ Biotech Index. biz.yahoo.com I also owOldAIMGuy-5/18/2004
997Appears that some of the institutions that bought on the upgrades durin the pastIan@SI-5/3/2004
996Potential Factive Market? For Gonorrhea treatment CDC is recommending switch frExtra Pale-4/26/2004
995Old (though not very) anti-infective collaboration with ArQule . . . may ntuck-4/25/2004
994Up almost 10% today on 5 times normal volume with no news... One has to wonder Ian@SI-4/19/2004
993Ha! Thanks for biting! Why, is there some sort of advantage to Factive, DDI? scaram(o)uche-4/2/2004
992DrugDrugInteraction. Ha! Look at me! Thanks for the slooow pitch. ;-)keokalani'nui-4/2/2004
991Jim: I wouldn't presume to be able to answer your questions, but I'll tscaram(o)uche-4/1/2004
990from 8-K, 8 March 2004...... <i>In early 2003, Genome Therapeutics took ascaram(o)uche-3/31/2004
989Rick- Have you seen any projections for Factive sales? In the past public presBiotech Jim-3/30/2004
988Genome Therapeutics to Present at Future Leaders in the Biotech Industry Conferescaram(o)uche-3/30/2004
987Hi Q, Thanks, All I got was the annual report in this mailing. No proxy, which IOldAIMGuy-3/28/2004
986Tom, Check the proxy statement that should have accompanied your Annual Report.quidditch-3/27/2004
985Hi RH and All, So far I've not been able to find anything on a suggested naOldAIMGuy-3/27/2004
984yahoo.businessweek.com MARCH 15, 2004 THE BIOTECH BEAT By Amy Tsao A Risky scaram(o)uche-3/20/2004
983Haven't got it yet, thanks. Went to Edgar for a look. Oscient? Ugh, ugh, scaram(o)uche-3/20/2004
982Yes - I agree, the name is puzzling. Where on earth did they come up with it?!!Starlight-3/20/2004
981Re: Oscient Pharma--Well, at least two reasons for the recent swoon are now appaquidditch-3/20/2004
980Hi Ian, Good news this AM. Genome Therapeutics (ticker: GENE, exchange: NASDAQ)OldAIMGuy-2/18/2004
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News